Figure 4
IDX combined with cis induces T cells migration towards tumor cells via CXCL10/type I IFN axis
(A) CD45+ for total leukocytes migrate towards C17 and NPC43+ve tumor cell lines following IDX and cis treatments alone or combined were measured in flow cytometry. (B) Specific migratory effects of the % CD3 T cells/CD45 cells, ** p<0.01 when compared to control (DMSO). (C) % CD4 helper T cells/CD3 cells, (D) % CD8 cytotoxic T cells/CD3 cells and (E) % double positive CD4 CD8 cells/CD3 cells (E) relative control (DMSO) were quantified. * p≤0.05 when compared to control (DMSO). (F) Tumor cells were pre-treated with brefeldin A (5 µg/mL) followed by treatment with the drugs alone/combined at the indicated concentrations for 8 hours Western blots were performed on the cell lysates with the indicated antibodies. p-IRF (396) and p-IRF (386) indicate phosphorylated serine 396 and 386, respectively. (G) Antibody array analysis of inflammatory cytokines in conditioned media from indicated NPC cell line following treatment with IDX, cis or combinations of both. Most prominently induced cytokines are highlighted in colored boxes. Quantitation of relative fold induction of cytokines compared with DMSO control cells were measured. Data are representative of two independent experiments. Statistical significance was analyzed using 2-way ANOVA * p≤0.05, ** p<0.01, *** p < 0.001, **** p < 0.0001 relative to control.